Vanguard Group Inc. Raises Position in Savara Inc (NASDAQ:SVRA)

Vanguard Group Inc. lifted its position in Savara Inc (NASDAQ:SVRA - Free Report) by 4.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,309,970 shares of the company's stock after purchasing an additional 365,959 shares during the period. Vanguard Group Inc. owned 4.84% of Savara worth $25,512,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of SVRA. Rosalind Advisors Inc. purchased a new stake in shares of Savara in the 4th quarter worth approximately $8,151,000. State Street Corp grew its holdings in Savara by 15.7% in the third quarter. State Street Corp now owns 4,138,276 shares of the company's stock worth $17,546,000 after purchasing an additional 560,242 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Savara by 10.8% during the third quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company's stock worth $11,564,000 after purchasing an additional 264,825 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Savara during the 4th quarter valued at $798,000. Finally, Barclays PLC raised its stake in Savara by 217.5% in the third quarter. Barclays PLC now owns 231,005 shares of the company's stock valued at $979,000 after buying an additional 158,244 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. HC Wainwright restated a "buy" rating and set a $6.00 price target on shares of Savara in a research note on Friday, March 28th. Wells Fargo & Company started coverage on Savara in a research report on Friday, December 20th. They set an "overweight" rating and a $8.00 price target on the stock. Finally, JMP Securities reissued a "market outperform" rating and issued a $9.00 price objective on shares of Savara in a report on Thursday, December 19th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Savara presently has an average rating of "Moderate Buy" and an average target price of $8.83.

Savara Price Performance

NASDAQ SVRA traded up $0.08 on Friday, hitting $3.01. The company had a trading volume of 465,408 shares, compared to its average volume of 1,315,155. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The company has a market capitalization of $519.63 million, a PE ratio of -7.00 and a beta of 0.52. Savara Inc has a 12-month low of $2.26 and a 12-month high of $5.31. The company's fifty day moving average price is $2.73 and its 200-day moving average price is $3.10.

Savara (NASDAQ:SVRA - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The business had revenue of $0.27 million for the quarter. As a group, analysts predict that Savara Inc will post -0.45 earnings per share for the current year.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.